Response gene to complement 32, a novel hypoxia-regulated angiogenic inhibitor

Circulation

Volumn 120, Issue 7, 2009, Pages 617-627

  An, Xiaojin ^a,b   Jin, Yi ^a,b   Guo, Hongnian ^b   Foo, Shi Yin ^b   Cully, Brittany L ^b   Wu, Jiaping ^b   Zeng, Huiyan ^b   Rosenzweig, Anthony ^b   Li, Jian ^a,b  

^a PEKING UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Apoptosis; Endothelium; Gene therapy; Hypoxia; Ischemia

Indexed keywords

ANGIOGENESIS INHIBITOR; CASPASE 3; CYCLIN E; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1; MATRIGEL; RESPONSE GENE TO COMPLEMENT 32; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL; CAPILLARY DENSITY; COLON TUMOR; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; EXPERIMENTAL MOUSE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LIMB ISCHEMIA; MALE; MIGRATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; APOPTOSIS; CAENORHABDITIS ELEGANS PROTEINS; CELL CYCLE PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN E; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MICE, NUDE; MUSCLE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; NERVE TISSUE PROTEINS; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69549120060     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.841502     Document Type: Article

References (30)

1. Simons M. Angiogenesis: where do we stand now? Circulation. 2005; 111:1556-1566.
2. Stempien-Otero A, Karsan A, Cornejo CJ, Xiang H, Eunson T, Morrison RS, Kay M, Winn R, Harlan J. Mechanisms of hypoxia-induced endo-thelial cell death: role of p53 in apoptosis. J Biol Chem. 1999;274: 8039-8045.
3. Li J, Sellke FW. Cardiomyocytes-endothelial cell interaction. New York, NY: Cambridge University Press. Endothelial Biomedicine. 2007: 602-608.
4. Badea T, Niculescu F, Soane L, Fosbrink M, Sorana H, Rus V, Shin ML, Rus H. RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem. 2002;277:502-508.
5. Oram SW, Liu XX, Lee TL, Chan WY, Lau YF. TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells. BMC Cancer. 2006;6:154.
6. Saigusa K, Imoto I, Tanikawa C, Aoyagi M, Ohno K, Nakamura Y, Inazawa J. RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest. Oncogene. 2007;26: 1110-1121.
7. Vlaicu SI, Cudrici C, Ito T, Fosbrink M, Tegla CA, Rus V, Mircea PA, Rus H. Role of response gene to complement 32 in diseases. Arch Immunol Ther Exp (Warsz). 2008;56:115-122.
8. Wu G, Mannam AP, Wu J, Kirbis S, Shie JL, Chen C, Laham RJ, Sellke FW, Li J. Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF. Am J Physiol Heart Circ Physiol. 2003;285:H2420-H2429.
9. Horowitz A, Murakami M, Gao Y, Simons M. Phosphatidylinositol-4,5- bisphosphate mediates the interaction of syndecan-4 with protein kinase C. Biochemistry. 1999;38:15871-15877.
10. Zeng H, Qin L, Zhao D, Tan X, Manseau EJ, Van Hoang M, Senger DR, Brown LF, Nagy JA, Dvorak HF. Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity. J Exp Med. 2006;203:719-729.
11. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol. 1998;152:1667-1679.
12. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43-54.
13. Hoang MV, Senger DR. In vivo and in vitro models of mammalian angiogenesis. Methods Mol Biol. 2005;294:269-285.
14. Folkman J. Antiangiogenesis in cancer therapy: endostatin and its mechanisms of action. Exp Cell Res. 2006;312:594-607.
15. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yanco-poulos GD, Wiegand SJ. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A. 2007;104:3219-3224.
16. Oettgen P. Transcriptional regulation of vascular development. Circ Res. 2001;89:380-388.
17. Fosbrink M, Cudrici C, Niculescu F, Badea TC, David S, Shamsuddin A, Shin ML, Rus H. Overexpression of RGC-32 in colon cancer and other tumors. Exp Mol Pathol. 2005;78:116-122.
18. Chen QM, Alexander D, Sun H, Xie L, Lin Y, Terrand J, Morrissy S, Purdom S. Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: induction of antiapoptosis, antioxidant, and detoxification genes. Mol Pharmacol. 2005;67:1861-1873.
19. Li F, Luo Z, Huang W, Lu Q, Wilcox CS, Jose PA, Chen S. Response gene to complement 32, a novel regulator for transforming growth factor-beta-induced smooth muscle differentiation of neural crest cells. J Biol Chem. 2007;282:10133-10137.
20. Conte C, Riant E, Toutain C, Pujol F, Arnal JF, Lenfant F, Prats AC. FGF2 translationally induced by hypoxia is involved in negative and positive feedback loops with HIF-1alpha. PLoS ONE. 2008;3:e3078.
21. Aparicio S, Sawant S, Lara N, Barnstable CJ, Tombran-Tink J. Expression of angiogenesis factors in human umbilical vein endothelial cells and their regulation by PEDF. Biochem Biophys Res Commun. 2005;326:387-394.
22. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 1994;90:649-652.
23. Olson NE, Kozlowski J, Reidy MA. Proliferation of intimal smooth muscle cells: attenuation of basic fibroblast growth factor 2-stimulated proliferation is associated with increased expression of cell cycle inhibitors. J Biol Chem. 2000;275:11270-11277.
24. Frederick TJ, Wood TL. IGF-I and FGF-2 coordinately enhance cyclin D1 and cyclin E-cdk2 association and activity to promote G1 progression in oligodendrocyte progenitor cells. Mol Cell Neurosci. 2004;25: 480-492.
25. Kano H, Arakawa Y, Takahashi JA, Nozaki K, Kawabata Y, Takatsuka K, Kageyama R, Ueba T, Hashimoto N. Overexpression of RFT induces G1-S arrest and apoptosis via p53/p21(Waf1) pathway in glioma cell. Biochem Biophys Res Commun. 2004;317:902-908.
26. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y. Angiogenic synergism, vascular stability and improvement of hindlimb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 2003;9:604-613.
27. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hemato-poietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194-1201.
28. Barclay C, Li AW, Geldenhuys L, Baguma-Nibasheka M, Porter GA, Veugelers PJ, Murphy PR, Casson AG. Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene. Clin Cancer Res. 2005;11:7683-7691.
29. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer. 2004;11:709-724.
30. Tanaka T, Takada H, Nomura A, Ohga S, Shibata R, Hara T. Distinct gene expression patterns of peripheral blood cells in hyper-IgE syndrome. Clin Exp Immunol. 2005;140:524-531.